secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001628280-24-005998
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead appoints Hongbo Lu to board; expands to 8 members
-----------------------------------------------------------

- Hongbo Lu, Ph.D., appointed as independent director effective April 1, 2024, increasing board from 7 to 8.
- Lu brings over 20 years of healthcare investment experience, including Managing Partner at Vivo Capital and LAV.
- She receives standard non-employee director compensation plus sign-on RSU grant valued at $761,666 vesting over three years.
- No family relationships or material interests with Arrowhead directors or officers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024005998/0001628280-24-005998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024005998/arwr-20240221.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-005998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer